Pemetrexed is a third generation multi-target agent able to inhibit at least three crucial enzymes involved in the folate pathway.Pemetrexedisindicatedincombinationwithcisplatinasfirstlinetreatmentofmalignantpleuralmesothelioma(MPM)and inmono-chemotherapyassecondlinetreatmentofadvancednon-small-celllungcancer(NSCLC).In2008,thecombinationofpemetrexedpluscisplatinhasgainedapprovalinEuropeandinUSAforfirstlinetherapylimitedtononsquamousNSCLCpatients.More recently,theoutcomeofalargephaseIIItrial,aimedatevaluatingpemetrexedasmaintenancetherapy,confirmedtheefficacyofthe druginnonsquamousNSCLCpatients.RecentdatasuggesttumourhistotypeandTSexpressionlevelsasthemostpromisingpredictors ofpemetrexedsensitivityinNSCLC. Theaimofthispaperistoreviewliteraturedataaboutplatinumandpemetrexedcombinationinadvancedsolidtumors,especially NSCLCandMPM.
Introduction
Inthelastfewdecades,severaleffortshavebeenmade to improve the outcome of patients affected by human malignanciesandtheefficacyachievablewithchemotherapy seems to have reached a therapeutic plateau. However, among newer cytotoxic agents, pemetrexed (ALIMTA ® Eli Lilly, Indianapolis, Indiana) gained much interest because of its peculiar mechanism of action. Pemetrexed is a multi-target agent that inhibits at least three crucial enzymes involved in the folate pathway: thymidylate synthase (TS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotideformyltransferase(GARFT).TSand DHFR are enzymes involved in pyrimidine synthesis process, whereas GARFT is a folate-dependent enzyme involved in de novo purine biosyntesis. 1 Purines and pyrimidines are both involved in the DNAsynthesis.Theabilityofpemetrexedtoinhibit multiple enzymes confers a clinical advantage by increasing the spectrum of tumors with biochemicalprofilespotentiallysensitivetothedrug.Among theseenzymes,TSisconsideredtheprimarytargetof pemetrexed.Infact,pemetrexedisonlyaweakinhibitorofGARFTandwhenTSisinhibited,oxidation oftetrahydrofolateisstopped,andthusDHFRactivity is unnecessary. 2 Basedonthesefindings,several trials have evaluated the interactions between pemetrexedandTS.Pre-clinicaldatahaveshownthatTS mRNA expression levels were inversely correlated with pemetrexed activity in different tumor cells. 3 Recently, TS resulted to be differentially expressed among different histotypes of non-small-cell lung cancer(NSCLC):inparticularTSishighlyexpressed insquamouscellcarcinomaandinhighgradecarcinoma,suggestingadifferentsensitivityprofiletothe drug,basedonhistology. 4 Thecurrentrecommended dosage for pemetrexed is 500 mg/mq intravenously every 3 weeks both alone and combined with other drugs. 5 Generally, pemetrexed is considered a well tolerateddrug.Myelo-suppressionwasthepredominant dose-limiting toxicity of pemetrexed reported in Phase I studies. Identification of the correlation between poor folate status and increased pemetrexed toxicityinamultivariateanalysisledtotherequirementoffolicacidandvitaminB12supplementation forpatientsinallpemetrexedstudies,witharesulting noted decrease in pemetrexed toxicity. 6 Thestandard dosefororalfolicacidis300-1000µgdaily,while forvitaminB12injectionis1000µgevery9weeks, beginningatleast1weekbeforepemetrexedadmin-istration and continuing until 3 weeks after the last administration. Moreover, the side effect of rush is reduced by the administration of dexamethasone (4mgorallytwicedaily)for3daysstartingtheday before pemetrexed infusion. The pharmacokinetics of pemetrexed, when administered as a single agent once every 21 days, have been examined. 7 Pemetrexed is predominantly eliminatedrenally.Pharmacokineticevaluationshave shown that pemetrexed is ∼80%proteinbound,with rapidplasmadistributionandeliminationphases,and exhibits linear pharmacokinetic over a broad range of doses (0.2-1,400 mg/m 2 ). Pemetrexed is rapidly eliminated from the plasma by urinary excretion [half-life(t1/2)=3.5hours],withabout70%to90% of the administered dose recovered unchanged in the urine within 24 hours. The steady-state volume of distributionofpemetrexedissmall(16L),suggesting limited tissue distribution. 8, 9 Mildnephrotoxicity occurred in patients treated with multiple cycles of therapy. Concurrent nonsteroidal anti-inflammatory agents have been excluded from pemetrexed trials because they may decrease the renal clearance of pemetrexed.
Cisplatin is also renally eliminated and is highly proteinbound(90%).Mostoftheplatinumderived from cisplatin is rapidly and irreversibly bound to plasma proteins. Whereas free platinum is rapidly eliminatedfromtheplasma(t1/2=0.5hour),t1/2of total platinum is 5.4 days +/−1,reflectingtheplasma protein binding. 10 The combination of pemetrexed with cisplatin resultedfeasibleandeffective.Thepharmacokinetics of total platinum and pemetrexed were evaluated in patientswithmalignantpleuralmesothelioma(MPM) usingpopulationpharmacokineticmethodsandthere wasnosignificantinfluenceofconcomitantcisplatin administration on pemetrexed clearance or of concomitant pemetrexed administration on cisplatin clearance.
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Moreover, the pha rmacokinetic of free platinum derived from cisplatin was not altered by co-administrationwithpemetrexed,andinagreement withthis,nounexpectedcisplatin-inducedtoxicities were observed when these drugs were combined.
Pemetrexed is currently approved in combination withcisplatinforfirstlinetreatmentofMPM, 12 as a single agent for second line treatment of advanced NSCLC 5 and has recently been approved in Europe andintheUnitedStatesforfirstlinetherapyincombination with cisplatin for non squamous NSCLC patients. Trials are also ongoing to test pemetrexed as single agent or in combination with other drugs in various solid tumors. 14, 15 This paper reviews data from literature of platinum and pemetrexed combinationinadvancedsolidtumors,especiallyMPMand NSCLC.
Malignant Pleural Mesothelioma First line treatment
The only FDA-approved agent for MPM is pemetrexed. Pemetrexed may be more active in mesothelioma than in other cancers because of the presence in these cells of a high capacity cell membrane transporter which is highly specific for pemetrexed. 16 In particular, pemetrexed was shown to have activity as a single agent in a phase II trial in patients with MPM 17 andinphaseItrialsincombinationwithplatinum analogs 18, 19 (Table1). The phase II clinical trial evaluated the efficacy ofpemetrexed(500mg/mq)forthetreatmentof64 MPM patientswith a histologicalprovendiagnosis, chemotherapy-naivemeasurablelesions,andadequate organ function. Most patients (43/64) also received folicacidandvitaminB12supplementationtoimprove safety.Assingleagent,pemetrexedresultedinamoderateresponserate(RR)(14.1%),withamediantimeto progression(TTP)of4.7monthsandamedianoverall survival (OS) of 10.7 months.
17 Seven of the nine responderswerevitaminsupplemented.Themedian (OS)was13.0monthsforsupplementedpatientsand 8.0monthsfornon-supplementedpatients.Vitaminsupplemented patients completed more cycles of therapythannon-supplementedpatients(median,six versustwocycles,respectively).Grade3/4neutrope-nia(23.4%)andgrade3/4leucopoenia(18.8%)were the most commonlaboratory toxicities.Fatigue and febrile neutropenia were the most commonly reported non-laboratoryevents(grade3,6.3%;grade4,0.0% each)andtheincidenceofthesetoxicitieswasgenerally lower in the vitamin-supplemented patients.
In a phase I trial designed to determine the maximum-tolerated dose (MTD), the dose-limiting toxicities(DLT),andthepharmacokineticsofpemetrexed combined with cisplatin, two patients had objective remissions of disease (one mesothelioma patient, one colon cancer patient). 18 The MTD was pemetrexed600mg/m 2 andcisplatin75mg/m 2 .DLTs wereneutropenicsepsis,diarrhea,andskintoxicity. In another phase I trial, the combination of pemetrexed plus carboplatin was found to be active and welltoleratedinMPMpatients,althoughnovitamin supplementation was administered. 19 The recommended dose of the combination for phase II studieswaspemetrexed500mg/m 2 and carboplatin area under the plasma concentration-time curve (AUC) 5mg/mL/min.
The use of pemetrexed in MPM patients was approved by the Food and Drug Administration (FDA) based on a single-blind, placebo-controlled, phase III study. In this trial, chemotherapy-naive The typical non-haematological toxicity profile of cisplatin (gastro-intestinal, neurologic, and renal) is questionableinthecontextofapalliativetreatment, especially for poor performance and elderly patients. Carboplatin has the potential advantages of havingabetteradverseeffectprofileandbettereaseof administration.InaphaseIstudyin25patientswith MPM,thecombinationofpemetrexedandcarboplatinwasactiveandwelltolerated,withareportedRR of 32%.
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Starting from these data, some combined schedulescontainingcarboplatin,insteadofcisplatin, weretestedinMPMpatientsinanattempttoreduce toxicity maintaining the same survival outcomes. 22, 23 In a phase II trial of 102 MPM patients treated with pemetrexed plus carboplatin, a similar time to progression (6.5 months) and overall survival (12.7months)wereobservedasinthephaseIIItrial of pemetrexed-cisplatin. 22 Thetoxicityprofileseemed to be better in the pemetrexed-carboplatin trial than in thepemetrexed-cisplatintrial,especiallyconsidering thenon-hematologicaltoxicity.A76-patientphaseII studyreporteda timetoprogression of8.0 months, amediansurvivalof14months,andaresponserate of25%usingthesameregimen. 23 Moreover,nosignificantdifferencewasobservedintermsofoverall disease control (60.4% vs. 66.9%, P = 0.47), TTP (7.2 vs. 7.5 months, P = 0.42) and survival (10.7 vs.13.9months,P =0.12)betweenelderlypatients compared with younger individuals in a retrospective analysisofpooleddatafromthetwophaseIItrialsof pemetrexedandcarboplatinasfirst-linetherapy. 24 Data from the International Expanded Access Program(EAP)suggestedanactivityofbothpemetrexed plus cisplatin and pemetrexed plus carboplatin in1704chemonaïveMPMpatientsnotamenableto curative surgery, showing similar time to progressive disease and 1-year survival rates. In particular, the pemetrexed plus cisplatin group obtained a RR of 26.3% compared with 21.7% for the pemetrexed plus carboplatin group, with 1-year survival rates of 63.1% versus 64.0% and medianTTP disease of 7 months versus 6.9 months.
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Thereareseveralunresolvedquestionsregarding timinganddurationofpemetrexedtreatment.Some epithelial mesothelioma patients may have prolonged stable disease for months or even years without chemotherapy. (There is no agreement about) It is not known whether these patients should be treated at diagnosis,atsymptomprogression,oratradiographic progression. In a very small pilot study from the RoyalMarsdenHospital,therewasatrendtowarda longer time to symptomatic progression and overall survival in those patients who received chemotherapy at diagnosis rather than at symptom progression; 26 however,theseresultsneedtobevalidatedinalarger study with a more active chemotherapy regimen than theoneemployedinthatstudy.Wealsodonotknow theoptimumtreatmentlength.Mostpatientsreceive between 4 and 8 cycles of pemetrexed with cis-or carboplatin,fewcantoleratemore.Shouldtheystop treatmentatthatpoint,orcontinuewithsingle-agent pemetrexed?A small, non-randomized Dutch feasibility study of pemetrexed maintenance demonstrated thatmaintenanceiswelltolerated,andthatresponses can occur after six cycles of treatment. 27 TheCancer andLeukemiaGroup(CALGB)iscurrentlydesigning a larger, randomized study to more definitively addressthisquestion.
Second line treatment
In the last years, pemetrexed has been extensively exploredassecond-linetherapyorbeyondinMPM patientsnotpreviouslyexposedtothisagent(Table2). Sørensenetalreportedtheresultsofastudyinwhich data sets of treatment of two different cohorts were combined.
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Thirty-nine patients previously treated with platinum-based regimens without pemetrexedwereincluded.Twenty-eightpatientsreceived pemetrexedalone(in3casesasthird-linetreatment), whereas 11 patients received pemetrexed plus carboplatin.Treatmentwasgenerallywelltolerated.Partial response(PR)rateswere21%and18%,medianTTP was 21 weeks and 32 weeks, and median survival was 42 weeks and 39 weeks with pemetrexed and pemetrexed/carboplatin, respectively. Jänne et al 29 reported the results of the use of pemetrexed alone or in combination with cisplatin within an Expanded AccessProgramin187patientswhohadreceivedpre-vious systemic chemotherapy. Patients were treated with pemetrexed alone (n = 91) or in combination with cisplatin (n = 96). Gemcitabine was the most common prior therapy used, followed by cisplatin, carboplatin,paclitaxelandvinorelbine.Responsedata wereavailablefor153patients.Theoverallresponse rate was 32.5% for pemetrexed/cisplatin and 5.5% forpemetrexedalone;stablediseasewasachievedin 36.3% and 41.1% of patients, respectively. Median OSwas7.6monthsinpatientsreceivingcombination therapy, and 4.1 months in those receiving singleagentpemetrexed.However,duetothelimitationsof thestudydesign,nocomparisoncanbedonebetween treatment groups. In fact, patients receiving combination chemotherapy were younger and fitter at baseline,andhadahigherresponseratetofirst-line treatment.Thisisreflectedbytheincreasednumber of treatment cycles administered to the combination therapygroup.InanotheranalysisfromtheExpanded AccessProgramdatabase,thesafetyandefficacydata ofMPMpatientswhoweretreatedwithsingle-agent pemetrexed were reported.
30 Ofatotalof812patients, 643wereevaluableforefficacy.Theoverallresponse rateforthepre-treatedpatients(n=396)was12.1%; medianTTPwas4.9months,andthemedianOSwas not estimable due to high censoring. Hematological toxicity was mild in both groups, with neutropenia (18%)asthemainsideeffect.
Theuseofpemetrexedinthissettingwasfurther exploredprospectivelyinarandomized,multi-center phase III study examining single-agent pemetrexed as second-line chemotherapy versus best supportive care(BSC).
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PrimaryendpointofthestudywasOS. SecondaryendpointsincludedRR,TTP,progressionfreesurvival(PFS),timetotreatmentfailure(TTF), and toxicity. Patients with relapsed MPM after first-line chemotherapy were randomly assigned to receive pemetrexed 500 mg/m 2 plus best supportive 
In conclusion, in pemetrexed-naïve patients, data from a randomized trial versus BSC suggest the use of single agent pemetrexed as a standard second-linetreatment.Thislineofevidenceissupported also by the results of the Expanded Access Programs.Inthegrowingpopulationofpemetrexedpretreatedpatients,thereisnostandardapproach.In selectedcaseswithaprolongedresponsetofirst-line pemetrexed-based chemotherapy, re-treatment with a pemetrexed-based regimen should be considered. When a trial is not available or patients are not eligible for an experimental approach, single agents vinorelbine or gemcitabine seem to be a reasonable option for palliation. However, second-line therapy inMPMremainsanidealfieldinwhichtotestnew chemotherapy agents as well as new therapeutic strategies.
Predictive factors of pemetrexed sensitivity in MPM
The combination of cisplatin/carboplatin and pemetrexedrepresentsthestandardofcareinthefirst-line treatment of MPM. However, more than one third of patients do not respond to this schedule, receiving useless toxicity. Considering the toxicity profile of this platinum compound containing schedule and thepoorperformancestatusofthemajorityofMPM patients, due to their advanced age and to the usual advanceddiseaseextensionatdiagnosis,itrepresents not only an important medical problem but also an needless expenditure of economical and human resources.Unfortunately,uptonowtherearenomany data about pemetrexed and/or cisplatin/carboplatin predictorsofresponseinMPMpatients. In a recent retrospectiveanalysis,Righietalinvestigatedthecorrelation between baseline gene expression levels of TSandexcisionrepaircross-complementationgroup 1(ERCC1),evaluatedbyreal-timepolymerasechain reaction and by immunohistochemistry (using the H-score), in MPM patients treated with pemetrexed (P)basedchemotherapy. Interestingly,thehigherTSexpression was associated with progressive disease (PD) (odds ratio1.02;P =0.061).Inparticular,theoddsratioof PDforpatientswithaTSexpression20%was11.7 (P =0.003),witharisktoprogressofapproximately 2 times higher than patients with a TS expression 20% (HR 1.90; P = 0.014). This trend was confirmedalsoforoverallsurvival(HR1.77;P =0.044). Onthebasisoftheseresults,TSexpressionmaybe considered as a potential predictor of response to the pemetrexed treatment in MPM patients. However, consideringitssignificantcorrelationwithresponse, PFS, and OS in a retrospective analysis, adequate prospectivestudiesareneededtoconfirmitspossible predictiveand/orprognosticrole.
Non-Small-Cell Lung Cancer
Second line treatment AtthebeginningPemetrexedwasinvestigateassingle agentinpreviouslytreatedmetastaticNSCLCpatients. InaphaseIIstudyconductedin81NSCLCpatients who had progressed during or within 3 months after firstlinechemotherapy,pemetrexeddemonstratedinan intent-to-treatpopulationaresponserate(RR)of8.9% and a median overall survival (OS) of 5.7 months.
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Based on these data, a phase III trial was conducted to compare pemetrexed to docetaxel, the standard second line chemotherapy. 5 Inthisstudy,571patients which had progressed after first line chemotherapy wererandomizedtopemetrexed(500mg/m 2 on day 1 every21days)ordocetaxel(75mg/m 2 on day 1 every 21days).AllstudypopulationreceivedfolateandvitaminB12supplementation,accordingtotheresultsof Scagliotti's study showing that pemetrexed therapy without vitamin supplementation resulted in significantly higher haematological and non haematological toxicity. 17 Nosignificantdifferencebetweenpemetrexed anddocetaxelwasobservedintermsofRR(9.1%ver-sus8.8%,P =0.10)orintermsofsurvival(medianOS 8.3versus7.9months;1-yearsurvival=29.7%inboth groups;hazardratio0.99).Patientsreceivingdocetaxel weremorelikelytohavegrade3-4neutropenia(40.2% versus 5.3%, P  0.01), febrile neutropenia (12.7% versus 1.9%, P  0.01), neutropenia with infections (3.3% versus 0%, P = 0.04), hospitalizations due to other drug related adverse events (10.5% vs. 6.4%; P =0.092),useofgranulocytecolony-stimulatingfactorsupport(19.2%vs.2.6%,P 0.001),andallgrade alopecia(37.7%vs.6.4%;P 0.001)comparedwith patients receiving pemetrexed. Based on theseresults, pemetrexedwasapprovedin2004byFoodandDrug Administration (FDA) for second line treatment of advancedNSCLC.
The introduction of vitamin supplementation reducedthetoxicityprofileofpemetrexed,suggesting the administration of higher doses of pemetrexed. Two studies evaluated whether an increased dosage of pemetrexed resulted in an improvement of the efficacy. 35 Theaimwastoachieveabetteroutcomewith the combined schedule and the primary endpoint was mediantimetoprogression(TTP).Thecombination armachievedalongermedianTTP(4.2monthsversus 2.8months;HR=0.67;95%CI0.51-0.89,P =0.005). However,medianOS(7.6monthsversus8.0months; HR0.85;95%CI0.63-1.2;P =notsignificant)and overallRR(4%versus9%)werenotsignificantlydifferent. The frequency of treatment-related toxicity exceedinggrade2wasinferiorto5%forallcategories andwasmorefrequentlyobservedinthecombination arm. Hematologic toxicity was mild and only rarely complicatedbyclinicalsequelae.Hospitalizationfor febrileneutropeniawas2%inbotharms.Theauthors concluded that the combination of carboplatin and pemetrexed is effective and increases PFS. Table 3 shows the results of pemetrexed trials in metastatic NSCLCpatientstreatedinsecondlinesetting.
First line treatment
Severaltrialsevaluatedpemetrexedinfirstlinesetting as single agent as well as in combination with other drugs. Two small phase II trials have investigated pemetrexedasasingleagentinchemonaïveNSCLC patients. 38, 39 In both trials the primary endpoint was RR.Inthefirststudyconductedin59patients,pemetrexedwasadministeredatthedoseof600mg/m 2 on day1every21daysachievingaRRof16%,amedian OSof7.2months,anda1-yearsurvivalrateof32%.
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Grade3-4neutropeniaandskinrashwereobserved in42%andin31%ofpatientsrespectively.
In the second study, a total of 33 previously untreatedNSCLCpatientsreceivedpemetrexedat thedoseof600mg/m 2 every21days. 39 Theoverall RRwas23.3%,themedianOSwas9.2months,and 1-year survival rate was 25.3%. The toxicity profilewassimilartothepreviouslymentionedstudy, showinggrade3-4neutropeniaasthepredominant hematologictoxicity.Itistonotethat,atthattime, vitamin supplementation and pre-medication with dexamethasone were not yet instituted which may explain the low safety profile observed in these trials.
Morerecently,Gridellietal 40 conducted a randomized phase II study in unfit or elderly chemonaïve NSCLC patients exploring the role of pemetrexed as single agent versus pemetrexed/gemcitabine in sequential combination. Eighty-seven patients were randomized to receive single agent pemetrexed 500mg/m 2 onday1every21daysorpemetrexedatthe samedoseoncycles1and2followedbygemcitabine 1200mg/mqonday1and8every21dayoncycles 3 and 4. The patients treated in the sequential arm achievedahigherRR(11.6%versus4.5%)andlonger OS (5.4 versus 4.7 months) compared with patients treated in the single agent arm. Hematological and non hematological toxicity were mild in both arms. The study demonstrated a moderate activity and a goodsafetyprofileformetastaticNSCLCunsuitable for platinum based chemotherapy.
The encouraging single agent response rate observedinthephaseIItrialsledtoinvestigatecombination chemotherapy with pemetrexed and platinum compounds.SeveralphaseIIstudieswereconducted to investigate the efficacy of pemetrexed in combination with cisplatin. 41, 42 Shepherd et al enrolled 32 patientstoreceivepemetrexed500mg/m 2 on day 1 and cisplatin 75 mg/m 2 on day 1 every 3 weeks.
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All patients received prophylactic dexamethasone, without vitamin supplementation. The overall RR was 45% with median OS of 8.9 months.A similar trialwasconductedin36untreatedNSCLCpatients showinganoverallRRof39%andamedianOSof 10.9months. 42 Themostcommontoxicitywashaematologicalinbothtrials(grade3-4neutropeniain33% and28%ofpatientsintheShepherdandManegold trials, respectively; grade 3-4 thrombocytopenia in 3%ofpatientsinbothtrials)likelyduetotheabsence of vitamin supplementation. Theprimaryendpointwastodemonstrateabetterhealth-relatedqualityoflife(HRQoL) and toxicity profile in carboplatin/pemetrexed arm. NodifferencesinHRQoLwereseenbetweenthetwo arms.Significantlyfewerpatientsexperiencedgrade 3-4leucopoeniaincarboplatin/pemetrexedarm(23% versus 46%, respectively, P  0.001), neutropenia (40%versus51%,respectively;P =0.024),thrombocytopenia(29%versus43%,respectively,P 0.001) and need for transfusions of red blood cells (29% versus43%,respectively,P =0.03).Theoverallsurvivalwassimilarinthetwoarms(7.3forcarboplatin/ pemetrexed arm versus 7.0 months for carboplatin/ gemcitabinearm;P =0.63).However,thisstudydid not reveal any association between histology and survival(P =0.77).Table4showstheresultsofpeme-trexedpluscis/carboplatintrialsinmetastaticNSCLC patients treated in second line setting.
Role of pemetrexed in maintenance therapy
Maintenancetherapyisaprolongedtherapyattheend ofaspecifiednumberofcyclesoncediseasestabilizationortumorresponsehasbeenachieved,although a universalconsensusondefinitionofthistermhas notbeenreached.Pemetrexed,duetoitsgoodtoxicityprofileandeaseofadministration,isanidealdrug to be tested in this setting.
A recently published, randomized double-blind phase III trial tested efficacy and safety of pemetrexed versus placebo in advanced/metastatic NSCLC patients who did not progressed after four cycles of first line platinum-based chemotherapy.
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Patients were randomized with 2:1 ratio to pemetrexed500mg/m 2 onday1every21daysplusbest supportive care (BSC) or intravenous placebo plus BSC.Treatmentwascontinueduntildiseaseprogression or unacceptable toxicities. The primary endpoint was PFS. In the intention-to-treat population of663randomlyassignedpatients,thePFSwassignificantlyhigherwithpemetrexedthanwithplacebo (4.3versus2.6months;HR0.50,95%CI0.42-0.61; P  0.0001) as well as disease control rate (49.1% and 28.9% respectively in pemetrexed and placebo arm). Median OS in the intent-to-treat population also improved significantly with pemetrexed comparedtoplacebo(13.4versus10.6months;HR0.79, 95%CI0.65-0.95;P =0.012).Moreover,thetreatment with pemetrexed was well tolerated: hematological and non-hematological toxicities, which occurredmainlyinpemetrexedarm,wereconsidered mild.Apre-specifiedanalysisofsurvivalaccordingto histologyconfirmedalongerPFSandOSforpatients treated with pemetrexed limited to non-squamous histology.
Another study evaluated Pemetrexed in maintenance setting. 48 This was a phase II trial aiming to test efficacy and safety of pemetrexed, carboplatin and bevacizumab as first line therapy followed by maintenance pemetrexed and bevacizumab until disease progression or unacceptable toxicities. Fifty patientsreceivedpemetrexed500mg/m 2 ,carboplatin AUC 6 and bevacizumab 15 mg/kg every 3 weeks forsixcycles.Forty-ninepatientswereassessablefor response,achievinganoverallresponserateof55%. ThemedianPFSandOSwere7.8and14.1months respectively. The median number of cycles was six (induction plus maintenance therapy), among 30 patients(60%)enteredinmaintenancephase,9(18%) completed 18 cycles. Grade 3-4 hematological toxicitywasanemia(6%;0),neutropenia(4%;0),and thrombocytopenia(0;8%).Majornon-hematological toxicitiesincludedproteinuria(2%;0),venousthrombosis(4%;2%),arterialthrombosis(2%;0)andunexpecteddiverticulitis(6%;2%).
Takentogether,thesedatasuggestthatmaintenance therapy opens new perspectives for slowing disease progressionafterfirstlinechemotherapy.Nevertheless, there are some concerns to be highlighted: in the Ciuleanu trial, about 50% of patients in the placebo arm never received additional therapy after progression disease and out of those who received a second line chemotherapy only 18% was treated with pemetrexed. Moreover, this study was designed before the completion of the pivotal first line study of pemetrexed/cisplatin versus gemcitabine/cisplatin; therefore, before drawing definitive conclusions, safetyandefficacyofmaintenancepemetrexedshould beassessedafterfirstlinetreatmentwithpemetrexed containing regimens.
Predictive factors of pemetrexed sensitivity in NSCLC Untilsomeyearsago,thechoiceofaspecifictreatmentwasmainlybasedonclinicalfactorssuchasage, performancestatus,co-morbidities,safetyprofileand availability of chemotherapy drugs. The identification of prognostic and predictive factors is an importanttooltodecideacustomizedtherapyforaspecific patient population.To this regard, it is important to specify that prognostic factors affect the outcome regardlessofthetreatmentused,whilepredictivefactors provide information on outcome with regard to a specifictherapy. Several retrospective analysis looking at predictive factors of sensitivity to pemetrexed have been conducted since pemetrexed was approved forsecondlinetherapyinNSCLCpatients.
5 Retrospective analysis from pemetrexed versus docetxel trial 49 inpreviouslytreatedNSCLCpatientsevaluatedwhethertheefficacywasdifferentaccordingto histology.ACoxmodelofoverallsurvivalwasused totestforasignificanttreatmentbyhistologyinteraction and to estimate HR for OS and PFS. 50 The analysis demonstrated that non-squamous patients treated with pemetrexed had a statistically significant longer OS compared with those treated with docetaxel (9.3 versus 8 months respectively; HR 0.778,95%CI,0.607-0.997).Conversely,patients with squamous histology who received docetaxel experienced a statistically higher OS than those treated with pemetrexed (7.4 versus 6.2 months respectively; HR 1.563; 95% CI, 1.079-2.264). Interaction test by histology was also statistically significant(P =0.001).
In a Japanese randomized phase II trial evaluating two different dosages of pemetrexed in pretreated patient, a Cox multiple regression analysis identified some good prognostic factors such as gender (female), good performance status (PS), earlystagedisease,longerintervalsfrompriorchemotherapy and histologic type (non-squamous cell carcinoma). 36 Of note, the median survival time of patientswithnon-squamouscellcarcinomawassignificantlylongercomparedwiththosewithotherhistologicalsubtypes(16.0monthsversus9.3months; P =0.0026).Smitetal 37 inaphaseIItrialcomparing pemetrexed alone versus combination of pemetrexed plus carboplatin as second line therapy, investigated the presence of polymorphisms related to the enzymes involved in the folate pathway and theirassociationwithclinicaloutcome.Asignificant correlation between the methylenetetrahydrofolate reductase(MTHFR)C677Thomozygousmutation and an improved clinical outcome (P = 0.03) was found. However, there was not a significant correlation between genotypes and chemotherapy-related toxicity and between high and low TS expression genotypes and tumor histology (squamous versus non-squamous).
Recently,basedontheresultsofalargerandomizedphaseIIItrial,thecombinationofcisplatinplus pemetrexed gained approval in Europe and in the UnitedStatesforfirstlinetherapyfornon-squamous non small cell lung cancer patients. 13 This was the firstphaseIIIstudyinNSCLCshowing,inaprospectiveway,differencesinsurvivalbasedonhistology. Coxproportionalmodelswereusedfortreatment-byhistology interactions for OS and PFS (P = 0.002) indicating that patients with non-squamous histology who were treated with cisplatin plus pemetrexed had a longer OS and PFS than all other patients. Moreover, within non-squamous histological subgroups, adenocarcinoma and large cell carcinoma had a better outcome in terms of OS when treated withpemetrexed/cisplatinthangemcitabine/cisplatin combination (adenocarcinoma HR 0.84; 95% CI, 0.71-0.99,P =0.033;largecellcarcinomaHR0.67; 95%CI,0.48-0.96;P =0.027).
These data have been confirmed by another randomized double-blind phase III trial comparing efficacy and safety of pemetrexed versus placebo in advanced/metastatic NSCLC patients non progressed after four cycles of platinum-based chemotherapy as maintenance therapy. 47 Pemetrexed again showed a statistically significant superior PFS (4.5 versus 2.6 months; HR 0.44; P  0.0001) and OS (15.5versus10.3months,HR0.70,P 0.0001)in non-squamous histology compared with squamous histology (PFS 2.8 versus 2.6 months, HR 0.69, P = 0.89; OS 9.9 versus 10.8 months, HR 1.07, P = 0.67).Among patients with non-squamous disease,theimprovementinbothPFSandOSwassignificantforpemetrexedinadenocarcinomaandother NSCLCsubgroups.
A potential explanation of these results could be relatedtodifferentexpressionlevelsofTSinNSCLC histotypes. Preclinical studies have indicated that over-expression ofTS correlate with reduced sensitivity to pemetrexed. 51, 52 Consistingwiththesedata, CeppietalobservedhigherexpressionofTSinsquamous cell carcinoma compared with non-squamous histotypes(P 0.0001),providingarationalexplanation for better outcome among patients with adenocarcinoma treated with pemetrexed. 4 TSexpressionhas beentestedbothatmRNAandproteinlevelsinundifferentiated large cell carcinoma using desmocillin-3 (DSC-3) immunostaining as a marker of squamous cell differentiation 53, 54 showing higher TS levels in DSC-3positivecomparedtoDSC-3negativetumors (P =0.02).Furthermore,Monicaetal 55 reported a differentialTSmRNAexpressionintwogroupsoflarge cell carcinoma (LCC). Specifically, non-neuroendocrine LCCs had different TS expression, based on theirphenotypes:TSlevelswerehigherinthegroup expressingtheadenocarcinomalineagemarkers,confirmingagaintheroleofhistology.
Other Solid Tumors
Multiple Phase II clinical trials have demonstrated that pemetrexed has promising single-agent activity inmanyothersolidtumors,includinggastric,colon, pancreatic, breast cancers, bladder, head and neck, and cervical cancers. [56] [57] [58] [59] Combinationregimensconsisting of pemetrexed and other chemotherapeutics or novel molecular-targeted agents are currently under investigation.Thecombinationpemetrexed/cisplatin wasevaluatedinheadandneckandgastriccancers.
Head and neck cancer
Cisplatinmonotherapyisastandardofcareinpatients withadvancedheadandneckcancer(HNC).Single agent pemetrexed has shown promising activity in patientswithlocallyadvancedormetastaticHNC. 60 In a phase I study conducted in approximately 12 patientswithadvancedsolidtumors,3patientswith HNC had partial responses to combined treatment with cisplatin and pemetrexed. 61 An ongoing phase III study is evaluating pemetrexed in combination with cisplatin versus cisplatin alone in patients with recurrent/metastatic head and neck cancer [www. clinicaltrials.gov].
Gastric cancer
InaphaseIItrial,pemetrexedshowedanoverallRRof 21%inpatientswithadvancedgastriccancer. 62 Pemetrexed in combination with cisplatin has shown additive or synergistic activity in gastric cancer cells and human tumor xenografts. 63 InaphaseIIstudy,51chemonaive patients with advanced gastric cancer received pemetrexed500mg/mqandcisplatin75mg/mqday1,every 3 weeks plus vitamin supplementation.
64
Of the 50 patientsevaluableforefficacy,13hadpartialresponse for an overall RR of 26% (95% CI, 14.6%-40.3%) and 15 (30%) had stable disease. Median TTP was 2.8months(95%CI,2.2-4.4months),andmedianOS was6.6months(95%CI,4.8-10.4months).Ofthe51 patientsevaluableforsafety,themostfrequentNCI-CTC grade 3/4 toxicities were neutropenia in 49% of patients (25% of cycles) and anorexia in 10% of patients(4%ofcycles).Recently,inaphaseIIstudy, the pemetrexed/oxaliplatin combination showed a responserate(36%;16/44patients;4CRand12PR), timetotumourprogression(6.2months),andsurvival (10.8months)comparabletothoseachievedinstudiesusingdifferent5-fluorouracil(5-FU)-oxaliplatin combinations,withouttheinconvenienceofprolonged 5-FUschedules,inchemonaivepatientswithadvanced gastric cancer. 65 Inconclusion,thepemetrexed/cisplatin combination has a modest activity and acceptable toxicityprofileinpatientswithadvancedgastriccancer. TherearenotyetphaseIIItrialsongoingorplanning to evaluate the impact of this combination on survival in gastric cancer.
Conclusions
Pemetrexed is a multitargeted antifolate that has demonstratedantitumoractivity,asasingleagentandin combinationwithotherchemotherapeuticagents,in various tumor types, especially MPM and NSCLC. Myelo-suppression was the predominant doselimitingtoxicityofpemetrexed.However,theadditionoffolicacidandvitaminB12markedlyimproved its safety, also when combined with cisplatin. The combination of pemetrexed with cisplatin resulted feasibleandeffective,withoutpharmacokineticinterferences.Actually,pemetrexed/cisplatincombination iscurrentlyapprovedforfirstlinetreatmentofMPM and it has recently gained approval in Europe and in theUnitedStatesforfirstlinetherapyfornonsquamousNSCLCpatients.Moreover,theresultsobtained about the role of pemetrexed as a maintenance therapy inNSCLCopennewperspectivesforslowingdisease progressionafterfirstlinechemotherapy.Resultsin othersolidtumorsarestillpreliminary.Thetumour histotype and TS expression levels seem to predict sensitivitytopemetrexedinNSCLCandtheidentification of predictors of response will be an interesting fieldofstudytobetterdefinethecancerpatientpopulationthatreallybenefitsfromthiscombination.
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